Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type

Modern Pathology

Volumn 22, Issue 11, 2009, Pages 1401-1414

  Weigelt, Britta ^a,c   Geyer, Felipe C ^b   Horlings, Hugo M ^a   Kreike, Bas ^a   Halfwerk, Hans ^a   Reis Filho, Jorge S ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Breast cancer; Classification; Histological type; Microarrays

Indexed keywords

ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MUCINOUS CARCINOMA; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; TRANSCRIPTOMICS;

ADENOCARCINOMA, MUCINOUS; ANTIGENS, CD56; BREAST NEOPLASMS; CARCINOMA, NEUROENDOCRINE; CHROMOGRANINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME; HUMANS; IMMUNOHISTOCHEMISTRY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; STAINING AND LABELING; SYNAPTOPHYSIN; TUMOR MARKERS, BIOLOGICAL;

EID: 70350683812     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.112     Document Type: Article

References (51)

1. Ellis P, Schnitt SJ, Sastre-Garau X, et al. Invasive breast carcinoma. In: Tavassoli FA, Devilee P (eds). WHO Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press: Lyon, 2003, pp 9-47
2. Reis-Filho JS, Lakhani SR. Breast cancer special types: why bother? J Pathol 2008;216:394-398
3. Capella C, Eusebi V, Mann B, et al. Endocrine differentiation in mucoid carcinoma of the breast. Histopathology 1980;4:613-630
4. Papotti M, Macrí L, Finzi G, et al. Neuroendocrine differentiation in carcinomas of the breast: a study of 51 cases. Semin Diagn Pathol 1989;6:174-188
5. Maluf HM, Zukerberg LR, Dickersin GR, et al. Spindle-cell argyrophilic mucin-producing carcinoma of the breast. Histological, ultrastructural, and immunohisto-chemical studies of two cases. Am J Surg Pathol 1991;15:677-686
6. Papotti M, Gherardi G, Eusebi V, et al. Primary oat cell (neuroendocrine) carcinoma of the breast. Report of four cases. Virchows Arch A Pathol Anat Histopathol 1992;420:103-108
7. Sapino A, Righi L, Cassoni P, et al. Expression of the neuroendocrine phenotype in carcinomas of the breast. Semin Diagn Pathol 2000;17:127-137
8. Zekioglu O, Erhan Y, i1 M, et al. Neuroendocrine differentiated carcinomas of the breast: a distinct entity. Breast 2003;12:251-257
9. Nassar H, Qureshi H, Volkanadsay N, et al. Clinico-pathologic analysis of solid papillary carcinoma of the breast and associated invasive carcinomas. Am J Surg Pathol 2006;30:501-507
10. Maluf HM, Koerner FC. Carcinomas of the breast with endocrine differentiation: a review. Virchows Arch 1994;425:449-457
11. Sapino A, Papotti M, Righi L, et al. Clinical significance of neuroendocrine carcinoma of the breast. Ann Oncol 2001;12:S115-S117
12. Miremadi A, Pinder SE, Lee AH, et al. Neuroendocrine differentiation and prognosis in breast adenocarcino-ma. Histopathology 2002;40:215-222
13. Makretsov N, Gilks CB, Coldman AJ, et al. Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol 2003;34:1001-1008
14. Louwman MW, Vriezen M, van Beek MW, et al. Uncommon breast tumors in perspective: incidence, treatment and survival in the Netherlands. Int J Cancer 2007;121:127-135
15. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752
16. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-8423
17. Hu Z, Fan C, Oh D, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006;7:96
18. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple negative/basal-like breast carcinomas. Breast Cancer Res 2007;9:R65
19. Weigelt B, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008;216:141-150
20. Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat 2008, e-pub ahead of print; doi:10.1007/s10549-008-0197-9
21. Lien HC, Hsiao YH, Lin YS, et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene 2007;26:7859-7871
22. Bertucci F, Finetti P, Cervera N, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006;66:4636-4644
23. Jacquemier J, Padovani L, Rabayrol L, et al. Typical medullary breast carcinomas have a basal/myoepithe-lial phenotype. J Pathol 2005;207:260-268
24. Vincent-Salomon A, Gruel N, Lucchesi C, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007;9:R24
25. Azoulay S, Lae M, Freneaux P, et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favourable outcome. Mod Pathol 2005;18:1623-1631
26. Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathol-ogy 2006;49:10-21
27. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008;26: 2568-2581
28. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007;26:2126-2132
29. López-Bonet E, Alonso-Ruano M, Barraza G, et al. Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochem-ical profiling. Oncol Rep 2008;20:1369-1374
30. Kreike B, Halfwerk H, Armstrong N, et al. Local recurrence after breast conserving therapy in relation to gene expression patterns in a large series of patients. Clin Cancer Res 2009;15:4181-4190
31. Moolenaar CE, Muller EJ, Schol DJ, et al. Expression of neural cell adhesion molecule-related sialoglycopro-tein in small cell lung cancer and neuroblastoma cell lines H69 and CHP-212. Cancer Res 1990;50: 1102-1106
32. Eisen M, Spellman P, Brown P, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-14868
33. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98: 5116-5121
34. Korkola JE, DeVries S, Fridlyand J, et al. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 2003;63:7167-7175
35. Tomasek JJ, Gabbiani G, Hinz B, et al. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002;3:349-363
36. Brennan KR, Brown AM. Wnt proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia 2004;9:119-131
37. Schambony A, Kunz M, Gradl D. Cross-regulation of Wnt signaling and cell adhesion. Differentiation 2004;72:307-318
38. Thorat MA, Marchio C, Morimiya A, et al. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. J Clin Pathol 2008;61:327-332
39. Wilson BJ, Giguere V. Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway. Mol Cancer 2008;7:49
40. Papotti M, Sapino A, Righi L, et al. 34betaE12 cytokeratin immunodetection in the differential diagnosis of neuroendocrine carcinomas of the breast. Appl Immunohistochem Mol Morphol 2001;9:229-233
41. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-1093
42. Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007;39:870-874
43. Garcia-Closas M, Hall P, Nevanlinna H, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 2008;4:e1000054
44. Schröder M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem 2005;74:739-789
45. Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 2005;115:2656-2664
46. Moenner M, Pluquet O, Bouchecareilh M, et al. Integrated endoplasmic reticulum stress responses in cancer. Cancer Res 2007;67:10631-10634
47. Hanna WM, Corkill M. Mucins in breast carcinoma. Hum Pathol 1988;19:11-14
48. Sáez C, Japón MA, Poveda MA, et al. Mucinous (colloid) adenocarcinomas secrete distinct O-acylated forms of sialomucins: a histochemical study of gastric, colorectal and breast adenocarcinomas. Histopathol-ogy 2001;39:554-560
49. Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008;7: 1013-1030
50. Fujii H, Anbazhagan R, Bornman DM, et al. Mucinous cancers have fewer genomic alterations than more common classes of breast cancer. Breast Cancer Res Treat 2002;76:255-260
51. Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat 2008;111:541-547